LCCC 1210 - Phase II, Multicenter, Single Arm Study of the Tolerability of Weekly Nab-paclitaxel as Second Line Treatment for Elderly Patients With Advanced Lung Cancer
Latest Information Update: 17 Sep 2021
Price :
$35 *
At a glance
- Drugs Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 25 Mar 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.
- 18 Feb 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Jan 2020.